Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.16) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.02), Briefing.com reports. Aurinia Pharmaceuticals had a negative return on equity of 27.47% and a negative net margin of 18,089.02%. The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.03 million. Aurinia Pharmaceuticals’s revenue was up .0% on a year-over-year basis.
Aurinia Pharmaceuticals (AUPH) opened at $5.00 on Thursday. Aurinia Pharmaceuticals has a 1-year low of $2.02 and a 1-year high of $10.54.
A number of equities analysts have commented on AUPH shares. Zacks Investment Research cut shares of Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. BidaskClub cut shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Monday, October 23rd. Leerink Swann upped their price objective on shares of Aurinia Pharmaceuticals from $10.00 to $14.00 and gave the company an “outperform” rating in a research note on Monday, October 23rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective (up previously from $10.00) on shares of Aurinia Pharmaceuticals in a research note on Monday, October 30th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $10.79.
ILLEGAL ACTIVITY WARNING: This report was first reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.themarketsdaily.com/2017/11/16/aurinia-pharmaceuticals-inc-auph-announces-earnings-results-misses-expectations-by-0-02-eps.html.
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.